Malignant trophoblastic neoplasia. Monitoring of therapy.
D000293:Adolescent; D000328:Adult; D002822:Choriocarcinoma / Q000188:drug therapy; D006063:Chorionic Gonadotropin / Q000652:urine; D003609:Dactinomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000188:drug therapy; D002820:Hydatidiform Mole, Invasive / Q000188:drug therapy; D007986:Luteinizing Hormone / Q000097:blood; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011247:Pregnancy; D011863:Radioimmunoassay; D013997:Time Factors; D014328:Trophoblastic Neoplasms / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000627:therapeutic use
D006063:Chorionic Gonadotropin; D004338:Drug Combinations; D003609:Dactinomycin; D014747:Vinblastine; D007986:Luteinizing Hormone; D008727:Methotrexate